WASHINGTON--(BUSINESS WIRE)--The nation’s allergists urged a Joint FDA Advisory Committee today to continue to make long-acting beta-2 agonists available for the treatment of moderate-to-severe asthma in appropriate patients.
WASHINGTON--(BUSINESS WIRE)--The nation’s allergists urged a Joint FDA Advisory Committee today to continue to make long-acting beta-2 agonists available for the treatment of moderate-to-severe asthma in appropriate patients.
